These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 25631772)

  • 21. Should the presence of minimal residual disease (MRD) in morphologic complete remission alter post-remission strategy in AML?
    Stone RM
    Best Pract Res Clin Haematol; 2011 Dec; 24(4):509-14. PubMed ID: 22127313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Co-expression of AML1-ETO and PML-RARa following treatment of de novo acute myeloid leukemia with AML1-ETO.
    Zhang S; Zhou W; Li Y; Yu S; Xue M; Qiao Y; Jian J; Liu B; Wang D
    Leuk Lymphoma; 2019 May; 60(5):1316-1319. PubMed ID: 30328750
    [No Abstract]   [Full Text] [Related]  

  • 23. Monitoring of post-transplant CBFB-MYH11 as minimal residual disease, rather than KIT mutations, can predict relapse after allogeneic haematopoietic cell transplantation in adults with inv(16) acute myeloid leukaemia.
    Tang FF; Xu LP; Zhang XH; Chen H; Chen YH; Han W; Wang Y; Yan CH; Sun YQ; Mo XD; Liu KY; Huang XJ
    Br J Haematol; 2018 Feb; 180(3):448-451. PubMed ID: 27650511
    [No Abstract]   [Full Text] [Related]  

  • 24. Quantitative PCR based minimal residual disease detection in core binding factor leukemias: prognostication and guiding of therapy.
    Schnittger S; Schoch C
    Leuk Res; 2006 Jun; 30(6):657-8. PubMed ID: 16386301
    [No Abstract]   [Full Text] [Related]  

  • 25. ASXL genes and RUNX1: an intimate connection?
    Metzeler KH
    Blood; 2014 Aug; 124(9):1382-3. PubMed ID: 25170110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Olaparib combined with low-dose chemotherapy for relapsed
    Lin L; Xue S; Chen J; Gu C; Zhang J; Xing E; Wang W; Wang L; Zhang Z
    Leuk Lymphoma; 2024 Aug; 65(8):1181-1185. PubMed ID: 39041737
    [No Abstract]   [Full Text] [Related]  

  • 27. Whole transcriptome sequencing of a paediatric case of de novo acute myeloid leukaemia with del(5q) reveals RUNX1-USP42 and PRDM16-SKI fusion transcripts.
    Masetti R; Togni M; Astolfi A; Pigazzi M; Indio V; Rivalta B; Manara E; Rutella S; Basso G; Pession A; Locatelli F
    Br J Haematol; 2014 Aug; 166(3):449-52. PubMed ID: 24673627
    [No Abstract]   [Full Text] [Related]  

  • 28. Myeloid neoplasms with t(16;21)(q24;q22)/RUNX1-RUNX1T3 mimics acute myeloid leukemia with RUNX1-RUNX1T1.
    Liu H; Wang SA; Schlette EJ; Xu J; Jorgensen JL; Cameron Yin C; Li S; Jeffrey Medeiros L; Tang G
    Ann Hematol; 2018 Oct; 97(10):1775-1783. PubMed ID: 29872884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High sensitivity and clonal stability of the genomic fusion as single marker for response monitoring in ETV6-RUNX1-positive acute lymphoblastic leukemia.
    Hoffmann J; Krumbholz M; Gutiérrez HP; Fillies M; Szymansky A; Bleckmann K; Zur Stadt U; Köhler R; Kuiper RP; Horstmann M; von Stackelberg A; Eckert C; Metzler M
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27780. PubMed ID: 31034759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subgroup Analysis Can Optimize the Relapse-Prediction Cutoff Value for WT1 Expression After Allogeneic Hematologic Stem Cell Transplantation in Acute Myeloid Leukemia.
    Qin YZ; Wang Y; Xu LP; Zhang XH; Zhao XS; Liu KY; Huang XJ
    J Mol Diagn; 2020 Feb; 22(2):188-195. PubMed ID: 31751675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias.
    Ommen HB; Schnittger S; Jovanovic JV; Ommen IB; Hasle H; Østergaard M; Grimwade D; Hokland P
    Blood; 2010 Jan; 115(2):198-205. PubMed ID: 19901261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia.
    Kim T; Moon JH; Ahn JS; Ahn SY; Jung SH; Yang DH; Lee JJ; Shin MG; Choi SH; Lee JY; Tyndel MS; Lee HY; Kim KH; Cai Y; Lee YJ; Sohn SK; Min YH; Cheong JW; Kim HJ; Zhang Z; Kim DDH
    Sci Rep; 2020 Nov; 10(1):20119. PubMed ID: 33208771
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical significance of minimal residual disease in childhood acute myeloid leukemia.
    Miyamura T; Sakata N; Okamura T; Yasui M; Inoue M; Yagi K; Sako M; Komada Y; Matsuyama T; Oda M; Park YD; Kawa K
    Int J Hematol; 2004 Apr; 79(3):243-9. PubMed ID: 15168592
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The t(8;21) fusion protein RUNX1-ETO downregulates PKM2 in acute myeloid leukemia cells.
    Yan JS; Li YD; Liu SH; Yin QQ; Liu XY; Xia L; Lu Y
    Leuk Lymphoma; 2017 Aug; 58(8):1985-1988. PubMed ID: 28092997
    [No Abstract]   [Full Text] [Related]  

  • 35. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia.
    Miyamoto T; Nagafuji K; Akashi K; Harada M; Kyo T; Akashi T; Takenaka K; Mizuno S; Gondo H; Okamura T; Dohy H; Niho Y
    Blood; 1996 Jun; 87(11):4789-96. PubMed ID: 8639850
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.
    Coltoff A; Houldsworth J; Keyzner A; Renteria AS; Mascarenhas J
    Ann Hematol; 2018 Jul; 97(7):1155-1167. PubMed ID: 29704019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Salmon-coloured granules in residual acute myeloid leukaemia with t(8;21)(q22;q22.1); RUNX1-RUNX1T1.
    Chen D; Chen W
    Br J Haematol; 2021 May; 193(4):691. PubMed ID: 33386742
    [No Abstract]   [Full Text] [Related]  

  • 38. Complex t(8;14;21)(q22;q13;q22), a variant of t(8;21), with t(15;21)(q15;p11) in a patient with acute myelogenous leukemia (M1).
    Takahashi T; Maruyama Y; Satoh Y; Yoshimoto M; Tsujisaki M
    Cancer Genet Cytogenet; 2004 Dec; 155(2):152-3. PubMed ID: 15571802
    [No Abstract]   [Full Text] [Related]  

  • 39. Molecular methods used for detection of minimal residual disease following hematopoietic stem cell transplantation in myeloid disorders.
    Elmaagacli AH
    Methods Mol Med; 2007; 134():161-78. PubMed ID: 17666750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Are kinases factors in core binding factor leukemia?
    Andolina JR; Corey SJ
    Leuk Lymphoma; 2009 Sep; 50(9):1397-8. PubMed ID: 19672779
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.